N-BUTYLTRIMETHOXYSILANE

We are N-BUTYLTRIMETHOXYSILANE CAS:1067-57-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Chemical Name:N-BUTYLTRIMETHOXYSILANE
CAS.NO:1067-57-8
Synonyms:Silane,butyltrimethoxy; 1-butyltrimethoxysilane; Butyl-trimethoxy-silan; BUTYLTRIMETHOXYSILANE; n-butyl(trimethoxy)silane;
Molecular Formula:C7H18O3Si
Molecular Weight:178.30200
 
Physical and Chemical Properties:
Density:0.896;
Boiling point:164^oC;
Flash point:43.1^oC;
Index of Refraction:1.3979;
 
Specification:
Appearance:Clear to straw liquid
Purity(GC):≥97.0%
 
Packing:180 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It may provide a hydrophobic surface treatment for inorganic powders orfiller materials.




Related News: In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.1463-10-1 Developing countries such as China and India have good foundations for undertaking global industrial transfers because of their comparative advantages. With the continuous improvement of China’s fine chemical technology level, the types of products and market shares in China’s undertaking industrial transfer have gradually increased.402-23-3 Developing countries such as China and India have good foundations for undertaking global industrial transfers because of their comparative advantages. With the continuous improvement of China’s fine chemical technology level, the types of products and market shares in China’s undertaking industrial transfer have gradually increased.4-Methoxypyridine The company’s iPSC product platform unites stem cell biology and precision genetic engineering to create renewable master engineered iPSC lines that can be repeatedly used to mass produce cancer-fighting immune cells, replacing the high production costs, weeks of manufacturing time, and complex engineering processes required for current-generation CAR T-cell immunotherapies with an off-the-shelf product that has the potential to reach many more patients.ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.